China Pharma Holdings (CPHI) Cost of Revenue (2010 - 2026)

China Pharma Holdings has reported Cost of Revenue for 17 years, with the latest figure at $95598.0 in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 9.74% year-over-year to $95598.0; the trailing twelve-month figure through Mar 2026 stood at $5.0 million (up 1.63% YoY), and the FY2025 full-year result was $4.3 million, down 34.36% from the prior year.
• Cost of Revenue for Q1 2026 stood at $95598.0, down from $4.0 million in the prior quarter.
• The five-year high for Cost of Revenue was $4.0 million in Q4 2025, with the low at -$4.3 million in Q4 2023.
• Historically, Cost of Revenue has averaged $638949.5 across 5 years, with a median of $266451.0 in 2022.
• Annual changes were most pronounced in 2022 — Cost of Revenue jumped 1466.5% — and 2023, when it plunged 1275.42%.
• China Pharma Holdings' Cost of Revenue stood at $364397.0 in 2022, then sank by 1275.42% to -$4.3 million in 2023, then soared by 130.22% to $1.3 million in 2024, then jumped by 209.73% to $4.0 million in 2025, then slumped by 97.62% to $95598.0 in 2026.
• The last three Cost of Revenue figures came in at $95598.0 (Q1 2026), $4.0 million (Q4 2025), and $815871.0 (Q3 2025), per Business Quant data.